Company intelligence / Profile preview

Rio Health

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Rio Health is a metabolic health company that provides a comprehensive weight management platform specifically designed for the GLP-1 era. The company integrates prescription GLP-1 receptor agonists, such as semaglutide and tirzepatide, with a digital ecosystem that includes personalized medical support, health coaching, and lifestyle monitoring. By focusing on a biology-first approach, Rio Health aims to help patients achieve sustainable weight loss and improve long-term metabolic outcomes. The platform is built to optimize the efficacy of modern weight-loss medications through data-driven insights and continuous clinical oversight.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small moleculePeptides
Industry: Non-Academic Healthcare

Beyond the preview

Go deeper on Rio Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rio Health.

Explore the full profile